RT Journal Article
SR Electronic
T1 BLOOD PROTEOMICS AND PAIN - A TRANSLATIONAL STUDY TO PROGNOSTICATE PAIN PHENOTYPES AND ASSESS NEW BIOMARKERS FOR PREVENTING PAIN IN HUMANS
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.04.24309933
DO 10.1101/2024.07.04.24309933
A1 Segelcke, Daniel
A1 Sondermann, Julia R.
A1 Kappert, Christin
A1 Pradier, Bruno
A1 Görlich, Dennis
A1 Fobker, Manfred
A1 Vollert, Jan
A1 Zahn, Peter K.
A1 Schmidt, Manuela
A1 Pogatzki-Zahn, Esther M.
YR 2024
UL http://medrxiv.org/content/early/2024/07/05/2024.07.04.24309933.abstract
AB Personalized strategies in pain management and prevention should be based on individual risk factors as early as possible, but the factors most relevant are not yet known. An innovative approach would be to integrate multi-modal risk factors, including blood proteomics, in predicting high pain responders and using them as targets for personalized treatment options. Here, we determined and mapped multi-modal factors to prognosticate a phenotype with high risk of developing pain and hyperalgesia after an experimental incision in humans. We profiled unbiased blood plasma proteome signature of 26 male volunteers, assessed psychophysical and psychological aspects before incision injury. Outcome measures were pain intensity ratings and the extent of the area of hyperalgesia to mechanical stimuli surrounding the incision as a proxy for central sensitization. Phenotype-based stratification resulted in the identification of low- and high-responders for the two different outcome measures. Logistic regression analysis revealed prognostic potential for blood plasma proteins and for psychophysical and psychological parameters. The combination of certain parameters increased the prognostic accuracy for both outcome measures, exceeding 97%. In high-responders, term-term-interaction network analysis showed a proteome signature of a low-grade inflammation reaction. Intriguingly, in silico drug repurposing indicates a high potential for specific antidiabetic and anti-inflammatory drugs already available. In conclusion, we show an integrated pipeline that provides a valuable resource for patient stratification and the identification of (i) multi-feature prognostic models, (ii) treatment targets, and (iii) mechanistic correlates that may be relevant for individualized management of pain and its long-term consequences.One Sentence Summary Unbiased identification of blood protein signatures in a translational human postoperative pain model provides new targets for managing pain.Competing Interest StatementMS received research awards and travel support by the German Pain Society (DGSS) both of which were sponsored by Astellas Pharma GmbH (Germany). MS received one-time consulting honoraria by Grunenthal GmbH (Germany). None of these funding sources influenced the content of this study, and MS declares no conflict of interest. During the past 5 yr, EPZ received financial support from Grunenthal for research activities and from Grunenthal, Novartis (Switzerland), Medtronic for advisory board activities, lecture fees, or both. None of this research support/funds was used for or influenced this manuscript, and EPZ declares no conflict of interest. The remaining authors declare that they have no conflicts of interest.Clinical TrialDRKS00016641Funding StatementFunding: Deutsche Forschungsgemeinschaft (DFG) (SCHM 2533/6e1 and SCHM 2533/4e1 to MS, PO1319/3e1 to EPZ). Federal Ministry of Education and Research (BMBF), Germany, to EPZ (01KC1903). University of Vienna to MS.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University Hospital Muenster of the local Ethics Committee of the Medical Faculty (registration no 2018-081-b-S)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors